半乳糖凝集素3表达与血液系统恶性肿瘤的相关性  

Correlation between Galectin-3 and hematologic malignant neoplasms

作　　者：高娜[1] 于文征[1] 

机构地区：[1]滨州医学院附属医院血液内科,256603

出　　处：《白血病．淋巴瘤》2017年第8期508-512,共5页Journal of Leukemia & Lymphoma

基　　金：滨州医学院校级科研计划（BY2013KJ38）

摘　　要：半乳糖凝集素3（Galectin-3）由LGALS3（14q21-22）基因编码,是Galectin家族的一员,由正常细胞及肿瘤细胞分泌,在血清及血浆中均可检测到,目前被认为可作为评估恶性肿瘤、心力衰竭患者病情的重要指标.Galectin-3在许多实体肿瘤中高表达,会导致患者对化疗药物敏感性差、治疗后易复发、生存率低、生存期短,可作为许多实体瘤包括甲状腺癌、胃癌、结肠癌、乳腺癌等的预后指标.近年来国外研究发现在多种血液系统恶性肿瘤中存在Galectin-3的高表达,且与疾病的预后密切相关.文章对Galectin-3与血液系统恶性肿瘤的相关性进行综述,旨在进一步探讨Galectin-3在血液系统恶性肿瘤中的表达情况及与肿瘤发生、发展及预后的关系,寻找血液系统恶性肿瘤Galectin-3靶向治疗的理论依据.Galectin-3, encoded by LGALS3 （14q21-22） and secreted by normal cells and tumor cells, is a member of Galectin family and can be detected both in serum and plasma. Galectin-3 is considered to be an important indicator of the assessment of the patients with malignant tumor and heart failure. The high expression of Galectin-3 may be correlated with poor response to chemotherapy, high recurrence rate, low survival rate and short survival period, which can be a prognostic marker in some solid tumors, including thyroid cancer, gastric cancer, colon cancer, breast cancer. Foreign studies have found that the high expression of Galectin-3 in many kinds of malignant tumors is closely related to the prognosis of the disease. In this paper, the correlation between Galectin-3 and blood tumors is reviewed to study the expression of Galectin-3 in the blood tumors and its relationship with the occurrence, development and prognosis of the tumor, and to explore the theoretical basis for the targeted therapy of Galectin-3.

关 键 词：半乳糖凝集素3 白血病 淋巴瘤 骨髓瘤 GALECTIN-3 

分 类 号：R733[医药卫生—肿瘤]